3rd Alpine Winter Conference on Medicinal and Synthetic Chemistry

 Virtual Event    January 24-28, 2022

Keynote Speakers

KL01 - Attenuating Oncogenic Transcription with Small Molecules

Prof. Angela KOEHLER
Prof. Angela KOEHLER
MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH, Cambridge, United States
Read more

KL03 - Functionalization of N-Heterocycles using Li, Mg, and Zn Organometallics

Prof. Paul KNOCHEL
Prof. Paul KNOCHEL
LUDWIG MAXIMILIANS UNIVERSITY, Munich, Germany
Read more

KL02 - Drug Discovery: Where are we Headed?

Dr Wendy YOUNG
Dr Wendy YOUNG
MPM CAPITAL, Brisbane, CA, United States
Read more

The "Catalytic Cycle" of Complex Molecule Synthesis and Methodology Development

IL23 - Flow-based Methods for Chemical Peptide and Protein Synthesis".

Prof. Nina HARTRAMPF
Prof. Nina HARTRAMPF
UNIVERSITY OF ZURICH, Zürich, Switzerland
Read more

IL24 - Prins Cyclization in Natural Product Synthesis

Prof. Ang LI
Prof. Ang LI
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China
Read more

IL25 - Taming Multifaceted Nickel Catalysts: An Academic Fascination

Prof. Ruben MARTIN
Prof. Ruben MARTIN
INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA, Tarragona, Spain
Read more

IL26 - Computationally Augmented Total Synthesis

Dr Timothy NEWHOUSE
Dr Timothy NEWHOUSE
YALE UNIVERSITY, New Haven, United States
Read more

Automation and Machine Learning Applications for Medicinal Chemistry

IL09 - Enabling Fragment-based Drug Discovery (FBDD) with Automated Synthesis Technologies

Dr Rachel GRAINGER
Dr Rachel GRAINGER
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
Read more

IL10 - Rapid Development of Robust Reactions and Multi-Step Syntheses

Prof. Alexei LAPKIN
Prof. Alexei LAPKIN
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

IL11 - High-Throughput Experimentation Capabilities to Accelerate Discovery Chemistry

Dr Iulia STRAMBEANU
Dr Iulia STRAMBEANU
JOHNSON AND JOHNSON, King of Prussia, United States
Read more

Methodologies to Understand Cellular Target Interaction

IL01 - Intracellular Oligonucleotide Distribution and Protein Binding

Dr Alice GHIDINI
Dr Alice GHIDINI
ASTRAZENECA, Gothenburg, Sweden
Read more

IL04 - Lessons in Transcellular Membrane Permeability Re-Learned

Dr Mike HANN
Dr Mike HANN
GSK MEDICINES RESEARCH CENTRE, Stevenage, United Kingdom
Read more

IL03 - Molecular Chameleonicity and Cell Permeability of Drugs and PROTACs in the bRo5 Space

Prof. Jan KIHLBERG
Prof. Jan KIHLBERG
UPPSALA UNIVERSITY, Uppsala, Sweden
Read more

IL02 - Monitoring Drug Selectivity and Target Engagement Across Systems – Thermal Shift Assay in Drug Discovery

Dr Anna RUTKOWSKA-KLUTE
Dr Anna RUTKOWSKA-KLUTE
GSK, Heidelberg, Germany
Read more

Understanding PK and PK/PD relationships in drug discovery - Target Mediated Drug Disposition

IL17 - Concept of Pharmacologic Target-Mediated Drug Disposition (TMDD) in Large-Molecule and Small-Molecule Compounds

Prof. Guohua AN
Prof. Guohua AN
THE UNIVERSITY OF IOWA COLLEGE OF PHARMACY, Iowa City, United States
Read more

IL18 - Understanding the PKPD and ADME of PF-07059013: An Allosteric Modulator of a High Abundance Target

Dr Kevin BEAUMONT
Dr Kevin BEAUMONT
ASTRAZENECA, Cambridge, United Kingdom
Read more

IL16 - General Introduction to TMDD

Dr David FAIRMAN
Dr David FAIRMAN
GSK, Cambridge, United Kingdom
Read more

IL19 - Importance of Mechanistic Models in AHD Prediction (IL)

Dr Birgit SCHOEBERL
Dr Birgit SCHOEBERL
NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Cambridge, MA, United States
Read more

Drug Discovery Tales (II)

OC06 - Towards the Design of Cell Division Cycle 25 Phosphatases Inhibitors as Anticancer Agents

Dr Carmen CERCHIA
Dr Carmen CERCHIA
UNIVERSITY OF NAPLES FEDERICO II, Naples, Italy
Read more

OC04 - Dissociative Inhibitors of Thymidylate Synthase Homodimer Accelerate its Proteasomal Degradation and Inhibit Cancer Growth in Vivo

Prof. Maria Paola COSTI
Prof. Maria Paola COSTI
UNIVERSITY OF MODENA AND REGGIO EMILIA, Modena, Italy
Read more

OC05 - Rational Design of Light-Controlled Bioactive Compounds for Photopharmacology

Mr Piermichele KOBAURI
Mr Piermichele KOBAURI
UNIVERSITY OF GRONINGEN FSSC, Groningen, The Netherlands
Read more

OC03 - Discovery of a Selective ALK2 Kinase Inhibitor for the Treatment of a Rare Genetic Bone Disease

Dr Thomas ULLRICH
Dr Thomas ULLRICH
NOVARTIS PHARMA AG, Basel, Switzerland
Read more

Increasing sp3 Fragment Options: Advances in the Synthesis of Small Ring Systems

IL12 - Exploring and exploiting propellanes

Prof. Ed ANDERSON
Prof. Ed ANDERSON
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

IL15 - No Strain, No Gain: Advances in the Synthesis and Design of New Classes of Building Blocks

Prof. Kevin BROWN
Prof. Kevin BROWN
INDIANA UNIVERSITY, Bloomington, United States
Read more

IL13 - The Next Generation of BCPs: Exploring Substitutions on the Bridge

Dr Xiaoshen MA
Dr Xiaoshen MA
MERCK & CO., INC, Boston, United States
Read more

IL14 - Synthesis and Functionalization of Cyclopropane Derivatives

Dr Sophie ROUSSEAUX
Dr Sophie ROUSSEAUX
UNIVERSITY OF TORONTO, Toronto, Canada
Read more

Covalent Targeting: Innovating for the Future

IL22 - Studies with Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors

Dr Agustin CASIMIRO-GARCIA
Dr Agustin CASIMIRO-GARCIA
PFIZER, United States
Read more

IL20 - Lysine-Targeting Covalent Inhibitors

Dr Matthew CHEESEMAN
Dr Matthew CHEESEMAN
THE INSTITUTE OF CANCER RESEARCH, Sutton, United Kingdom
Read more

IL21 - Reversible-covalent Inhibitors of the Kinase Activity of FGFR4

Dr Robin FAIRHURST
Dr Robin FAIRHURST
NOVARTIS, Basel, Switzerland
Read more

Drug Discovery Tales (I)

OC01 - Design and Synthesis of Novel RNA Binders for Therapeutic Applications

Ms Maurinne BONNET
Ms Maurinne BONNET
ICN, NICE, France
Read more

OC02 - Is Resistance Futile? Discovery of Clinical Candidate AZD3229, A Pan-Mutant C-KIT Inhibitor

Dr James SMITH
Dr James SMITH
ASTRAZENECA, Cambridge, United Kingdom
Read more

Targeting Unstructured Proteins

IL05 - Innovative Strategies to Target Non-Coding RNAs with Synthetic Ligands

Dr Maria DUCA
Dr Maria DUCA
UNIVERSITY OF CÔTE D'AZUR, Nice, France
Read more

IL07 - Drugging RNA – A Structure-based Approach

Dr Jacques DUMAS
Dr Jacques DUMAS
ARRAKIS THERAPEUTICS, Boston, United States
Read more

IL06 - Targeting Transcription Factors for Treating Human Cancers and Auto Immune and Inflammatory Diseases

Dr Doriano FABBRO
Dr Doriano FABBRO
CELLESTIA BIOTECH AG, Basel , Switzerland
Read more

IL08 - Design of Zotatifin (eFT226), a First-in-Class Inhibitor of the RNA Helicase eIF4A

Dr Christian NILEWSKI
Dr Christian NILEWSKI
GENENTECH, South San Francisco, United States
Read more